Adebrelimab plus chemo before surgery for high-risk breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a single breast cancer that is either large (≥2 cm with lymph node spread) or very large (≥5 cm), and is high-grade or aggressive.
- Your cancer must be hormone receptor positive (ER ≥1%) and HER2 negative (not the HER2-positive type).
- You must have a measurable tumor that can be seen on scans, and you must have a tissue sample (biopsy) available for testing.
- You are in good physical condition (ECOG 0 or 1, meaning you can do all your normal activities or are up and about more than half the day).
- You are not pregnant, not breastfeeding, and agree to use reliable birth control during treatment and for at least 6 months after.
- You have not had prior immunotherapy for cancer, do not have active autoimmune disease, and do not have serious infections or other recent cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
This trial tests a new treatment for a type of breast cancer that is hormone receptor-positive (HR+) and HER2-negative. The treatment combines a drug called adebrelimab with chemotherapy, given after a procedure called HIFU (high-intensity focused ultrasound) that uses sound waves to heat and destroy cancer cells. The goal is to see if this combination can improve outcomes before surgery.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.